We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LOOK ABROAD FOR COST-EFFECTIVENESS MODELS, EXPERTS SAY

LOOK ABROAD FOR COST-EFFECTIVENESS MODELS, EXPERTS SAY

April 28, 2006

The medical device industry must consider its role in cost containment and cost-effectiveness in the overall U.S. healthcare picture, argued experts at the recent World Healthcare Congress in Washington, D.C.

The U.S. healthcare system is lagging behind its fellow industrialized nations in terms of the quality and cost of healthcare, and the degree to which it is willing to learn from models in other countries may be key, experts said.

For example, healthcare systems in Taiwan and Canada involve partnering with device and drug industries to keep costs manageable. The Canadian model achieves buy-in from industry "upstream," said John Burns, senior vice president for investment programs management at Canada Health Infoways. He noted that building a business strategy through collaboration with provincial health ministries and other partners is an effective business model for managing costs.

Taiwan's system is similar to Japan's in that "we negotiate directly with vendors," Hong-Jen Chang, former CEO and president of Taiwan's Bureau of National Health Insurance (NHI) and CEO of Taiwan Global Biofund, told FDAnews.

The device industry has undermined cost-effectiveness by lobbying Congress to cease funding a now-defunct government initiative, Humphrey Taylor, chairman of the Harris Poll, told conference attendees April 17. He took industry and Capitol Hill to task for failing to streamline U.S. healthcare to model more efficient and higher-quality models in Canada, Europe and Asia. ()a href="http://www.fdanews.com/ddl/33_17/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing